Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5775 - Cell free Tumor-DNA can predict treatment outcome in advanced PDAC

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Translational Research

Tumour Site

Pancreatic Adenocarcinoma

Presenters

Sabine Payr

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

S. Payr1, J. Beck2, U. König1, M. Brunner1, J. Gaedcke3, A. Azizian3, M. Ghadimi3, V. Ellenrieder1, E. Schütz2, A. König1

Author affiliations

  • 1 Gastroenterology And Gastroenterological Oncology, Universitätsmedizin Göttingen, 37075 - Göttingen/DE
  • 2 Liquid Biopsy Center, Chronix Biomedical GmbH, Göttingen/DE
  • 3 Department Of General-, Visceral-, And Pediatric Surgery, Universitätsmedizin Göttingen, 37075 - Göttingen/DE

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5775

Background

Determination of chemotherapy response in pancreatic cancer (PDAC) relies on imaging such as CT or MRI scan, where reliable results can be obtained not earlier than 12 weeks after treatment start. Herein we report, that determination of cell-free DNA (cfDNA) can improve treatment monitoring and may allow prediction of treatment response after administration of the first cycle of chemotherapy.

Methods

26 patients with advanced PDAC were treated with the FOLFIRINOX regime. Cell-free DNA (cfDNA) was determined from blood samples before treatment start and before each cycle (d1 and d15) for 3 months. In a subset, cfDNA was also determined during first FOLFIRINOX administration after infusion of oxaliplatin and irinotecan (8hrs). Tumor status was evaluated before treatment start and after 3 month by CT scan. cfDNA was extracted from at least 2 mL of plasma and ≥10ng total cfDNA was used for sequencing library preparation. Sequencing reads, obtained with a NextSeq500 (Illumina) were mapped to the reference genome (HG19) and read counted in 701 bins of autosomes, with an average size of 5.5Mb. After normalization and transformation into log2 ratios, Z-values were calculated versus a healthy reference group (133 cfDNA samples). Z-Scores of bins significantly different from the reference were summed to generate the CNI-score.

Results

The risk of patients (n = 11) with an elevated pre-therapeutic CNI-Score of > 200 for not responding to chemo was 82%. Patients with CNI-Score above the 95thpercentile of the reference population (CNI >24) after cycle 3, had a significantly higher risk to progress (80%), with a 73% accuracy of prediction (p = 0.03). The prediction of therapy failure was even better after 4 cycles with a 90% predictive value and an overall 83% accuracy (p = 0.02). In 13 patients CNI-score was determined after 8hrs of initiation therapy to assess a possible cytolytic tumor burst. Only patients showing a significant increase of CNI-scores, compared to pre-therapeutic values were responders (n = 2), one of three stable patients had a borderline burst, whereas all progressive patients (n = 8) did not show any sign of tumor burst.

Conclusions

Determination of cell free DNA represents a powerful tool to predict outcome very early during medical treatment of advanced PDAC.

Clinical trial identification

Legal entity responsible for the study

Alexander König.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.